Related Experiment Video
Updated: Apr 26, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma
David M Miller, Keith T Flaherty, Hensin Tsao1
1Wellman Center for Photomedicine and Department of Dermatology, MGH Cancer Center, Massachusetts General Hospital, MA USA.
Abstract:
Key molecular and immunological insights over the past decade have radically changed the face of therapy in melanoma. Whereas 5 years ago, treatment for advanced melanoma was restricted to the alkylating agent dacarbazine and the immunostimulants interleukin-2 and interferon-α-2b, today the therapeutic menu includes precise therapies that target key determinants in oncogenic pathways and immune checkpoints. In this chapter, we will review the current status and future directions of targeted therapies for melanoma directed at mitogen-activated pathways and immune checkpoints.
Insights
Recent advances in melanoma treatment have shifted from traditional chemotherapy and immunotherapy to targeted therapies. These novel treatments focus on specific oncogenic pathways and immune checkpoints, offering new hope for advanced melanoma patients.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Melanoma treatment has evolved significantly over the last decade.
- Historically, treatment options were limited to dacarbazine, interleukin-2, and interferon-α-2b.
- Recent molecular and immunological discoveries have revolutionized melanoma therapy.
Purpose of the Study:
- To review the current landscape of melanoma targeted therapies.
- To discuss future directions in melanoma treatment strategies.
- To highlight therapies targeting oncogenic pathways and immune checkpoints.
Main Methods:
- Review of recent scientific literature.
- Analysis of current therapeutic options for advanced melanoma.
- Discussion of targeted agents and immunotherapies.
Main Results:
- The therapeutic options for advanced melanoma have expanded.
- Targeted therapies now include agents acting on mitogen-activated pathways.
- Immune checkpoint inhibitors represent a major advancement.
Conclusions:
- Targeted therapies and immune checkpoint inhibitors are transforming melanoma treatment.
- Future research will likely focus on refining these precise therapeutic strategies.
- Personalized medicine approaches are becoming central to melanoma management.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Microorganisms in Medicine and Therapeutics

